Medicare Enrolled
Dr. Azriel Hirschfeld, M.D.
Hematology & Oncology · Brooklyn, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Hirschfeld from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hirschfeld?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Hirschfeld
Dr. Azriel Hirschfeld is a hematology & oncology specialist in Brooklyn, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Hirschfeld performed 141,354 Medicare services across 1,397 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hirschfeld received a total of $39,567 from 74 pharmaceutical and/or device companies across 1107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hirschfeld is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 4% volume in NY
$39,567 industry payments
Medicare Practice Summary
Medicare Utilization ↗141,354
Medicare services
Top 4% in NY for hematology & oncology
1,397
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~7,068 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
82,986 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 15,431 | $0 | $0 |
| Injection, atropine sulfate, 0.01 mg | 12,884 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
7,172 | $0 | $13 |
| Injection, irinotecan, 20 mg | 4,083 | $1 | $2 |
| Injection, leucovorin calcium, per 50 mg | 3,371 | $1 | $4 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
3,160 | $27 | $96 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
2,488 | $1 | $2 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 2,141 | $1 | $7 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
1,280 | $141 | $276 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
1,061 | $126 | $458 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
848 | $8 | $21 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
675 | $62 | $342 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 650 | $1 | $130 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
484 | $12 | $358 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
468 | $15 | $127 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
414 | $27 | $485 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
352 | $8 | $45 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
341 | $1 | $16 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
248 | $124 | $677 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
177 | $99 | $220 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
167 | $61 | $265 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
121 | $232 | $740 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
90 | $0 | $28 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
84 | $19 | $354 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
51 | $83 | $254 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
43 | $53 | $85 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
36 | $30 | $357 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
26 | $13 | $34 |
| New patient office visit, complex (60-74 min) | 22 | $198 | $523 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.9% high complexity
93.8% medium
2.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$39,567
Total received (2018-2024)
Avg $5,652/year across 7 years
Top 13% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
74
Companies
1,107
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$20,983 (53.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,541 (39.3%)
Other
Charitable contributions, space rental, and other categories
$3,043 (7.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,853
2023
$2,387
2022
$4,225
2021
$4,705
2020
$3,962
2019
$11,081
2018
$10,355
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,071
Eisai Inc.
$248
Menarini Silicon Biosystems, Inc.
$246
AstraZeneca Pharmaceuticals LP
$191
Stemline Therapeutics Inc.
$158
Bayer Healthcare Pharmaceuticals Inc.
$134
Ipsen Biopharmaceuticals, Inc
$114
GlaxoSmithKline, LLC.
$108
PFIZER INC.
$91
Janssen Biotech, Inc.
$67
Gilead Sciences, Inc.
$61
Lilly USA, LLC
$55
Cumberland Pharmaceuticals, Inc.
$54
Exelixis Inc.
$42
E.R. Squibb & Sons, L.L.C.
$42
Aveo Pharmaceuticals, Inc.
$32
TAIHO ONCOLOGY, INC.
$27
ABBVIE INC.
$22
Tempus AI, Inc
$21
Daiichi Sankyo Inc.
$18
Merck Sharp & Dohme LLC
$18
SpringWorks Therapeutics, Inc.
$17
ARRAY BIOPHARMA INC
$16
Top 3 companies account for 54.8% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$17,500
Exelixis Inc.
$3,633
Novartis Pharmaceuticals Corporation
$3,559
PFIZER INC.
$1,537
Lilly USA, LLC
$1,217
E.R. Squibb & Sons, L.L.C.
$819
Janssen Biotech, Inc.
$818
Amgen Inc.
$786
Merck Sharp & Dohme Corporation
$684
Seagen Inc.
$666
Incyte Corporation
$648
Eisai Inc.
$594
Ipsen Biopharmaceuticals, Inc
$418
Rigel Pharmaceuticals, Inc.
$397
Astellas Pharma US Inc
$323
GENZYME CORPORATION
$303
Daiichi Sankyo Inc.
$295
GlaxoSmithKline, LLC.
$288
Taiho Oncology, Inc.
$267
Merck Sharp & Dohme LLC
$263
Boehringer Ingelheim Pharmaceuticals, Inc.
$252
Menarini Silicon Biosystems, Inc.
$246
Genentech USA, Inc.
$231
PUMA BIOTECHNOLOGY, INC.
$223
Gilead Sciences, Inc.
$215
EISAI INC.
$210
Stemline Therapeutics Inc.
$203
Foundation Medicine, Inc.
$189
Bayer Healthcare Pharmaceuticals Inc.
$184
Clovis Oncology, Inc.
$181
NOVARTIS PHARMACEUTICALS CORPORATION
$167
EMD Serono, Inc.
$149
ABBVIE INC.
$149
Cumberland Pharmaceuticals, Inc.
$135
Teva Pharmaceuticals USA, Inc.
$131
Bayer HealthCare Pharmaceuticals Inc.
$129
Nestle HealthCare Nutrition Inc.
$125
TESARO, Inc.
$125
MENARINI SILICON BIOSYSTEMS, INC.
$83
Puma Biotechnology, Inc.
$79
TAIHO ONCOLOGY, INC.
$74
Myriad Genetic Laboratories, Inc.
$71
Kyowa Kirin, Inc.
$70
Seattle Genetics, Inc.
$65
Celgene Corporation
$64
Sirtex Medical Inc
$63
Sun Pharmaceutical Industries Inc.
$63
ARRAY BIOPHARMA INC
$60
AVEO Pharmaceuticals, Inc.
$52
AbbVie, Inc.
$48
AbbVie Inc.
$40
Aveo Pharmaceuticals, Inc.
$32
Helsinn Therapeutics (U.S.), Inc.
$30
Verity Pharmaceuticals Inc.
$26
Acceleron Pharma, Inc.
$25
Regeneron Healthcare Solutions, Inc.
$25
Myovant Sciences Inc.
$23
Mylan Institutional Inc.
$23
TerSera Therapeutics LLC
$23
G1 Therapeutics, Inc.
$23
Alexion Pharmaceuticals, Inc.
$22
Coherus Biosciences Inc.
$22
Tempus AI, Inc
$21
Dova Pharmaceuticals
$20
Karyopharm Therapeutics Inc.
$20
Blue Earth Diagnostics Limited
$19
Spectrum Pharmaceuticals Inc.
$19
Novocure Inc.
$19
Blueprint Medicines Corporation
$18
SpringWorks Therapeutics, Inc.
$17
JAZZ PHARMACEUTICALS INC.
$16
Takeda Pharmaceuticals U.S.A., Inc.
$14
ImmunoGen, Inc.
$13
Janssen Pharmaceuticals, Inc
$9
Top 3 companies account for 62.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALUNBRIG · Abraxane · Alecensa · Avastin · Axumin · BALVERSA · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · Bavencio · CABOMETYX · CALQUENCE · COSELA · CREON · CYRAMZA · Cabometyx · Cellsearch · Creon · DARZALEX · Doptelet · ELAHERE · ELIQUIS · ELITEK · ENHERTU · ERBITUX · ERLEADA · Elahere · Enhertu · Erleada · FARESTON · FASLODEX · FOTIVDA · FOUNDATIONONE · GAVRETO · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INFUGEM · INJECTAFER · INLYTA · INQOVI · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · NERLYNX · Nerlynx · Neulasta · Nplate · Nubeqa · ODOMZO · OGSIVEO · OPDIVO · ORGOVYX · Ogivri · Onivyde · Optune · Orserdu · PADCEV · PIQRAY · POTELIGEO · PRECISETUMOR · Perjeta · RETEVMO · ROLVEDON · ROZLYTREK · RYBREVANT · Reblozyl · Revlimid · Rubraca · SANCUSO · SANDOSTATIN LAR · SARCLISA · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TECENTRIQ · TUKYSA · Tavalisse · Trelstar · Trodelvy · Truxima · Turalio · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · Vectibix · Venclexta · Vitrakvi · XALKORI · XGEVA · XOSPATA · XPOVIO · XT CDX · XTANDI · Xofigo · Xtandi · YONSA · ZEJULA · ZENPEP · ZEPZELCA · ZOLADEX · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (53%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
Hematology & oncology specialists within 10 mi
728
Per 100K population
27.5
County median income
$78,548
Nearest hospital
WOODHULL MEDICAL & MENTAL HEALTH CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Hirschfeld is a mixed practice specialist, with above-average Medicare volume (top 4% in NY), with speaking/promotional industry engagement in the top 13% of NY peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Hirschfeld experienced with oxaliplatin chemotherapy injection?
Based on Medicare claims data, Dr. Hirschfeld performed 82,986 oxaliplatin chemotherapy injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hirschfeld receive payments from pharmaceutical companies?
Yes. Dr. Hirschfeld received a total of $39,567 from 74 companies across 1,107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hirschfeld's costs compare to other hematology & oncology specialists in Brooklyn?
Dr. Hirschfeld's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hirschfeld) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Brooklyn
Browse hematology & oncology specialists in Brooklyn ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology